Severe gastrointestinal mucositis following high dose melphalan therapy for multiple myeloma

被引：2
|
作者：
Sharma, Sanjeev Kumar [1 ]
Handoo, Anil [1 ]
Choudhary, Dharma [1 ]
Dhamija, Gaurav [1 ]
Gupta, Nitin [1 ]
机构：
[1] BLK Superspecial Hosp, Dept Hematooncol & Bone Marrow Transplant, New Delhi 110005, India
来源：
WORLD JOURNAL OF GASTROENTEROLOGY | 2013年 / 19卷 / 05期
关键词：
Gastrointestinal mucositis; Chemotherapy; RISK-FACTORS;
D O I：
10.3748/wjg.v19.i5.784
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Mucositis is a known complication following use of chemotherapy, but fatal mucositis is unusual and management of such cases may be challenging. Pathologically there is denudation of mucosa of gastrointestinal tract. Severe cases can develop ileus and even perforation of bowel wall. We report here a case of multiple myeloma who developed World Health Organization grade 4 gut mucositis following the use of high dose melphalan with the expulsion of "intestine-like" material. (C) 2013 Baishideng. All rights reserved.
引用
收藏
页码：784 / 785
页数：2
相关论文
共 50 条
  • [21] INTERMITTENT MELPHALAN THERAPY IN MULTIPLE MYELOMA
    HOOGSTRATEN, B
    COSTA, J
    CUTTNER, J
    FORCIER, J
    LEONE, LA
    HARLEY, JB
    GLIDEWELL, OJ
    JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1969, 209 (02) : 251 - +
  • [22] High dose melphalan induces senescence features in multiple myeloma cells
    Guilatco, Angelo
    Borges, Gabriel Alvares
    Tchkonia, Tamar
    Kirkland, James L.
    Kourelis, Taxiarchis
    Drake, Matthew
    Weivoda, Megan
    JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 112 - 112
  • [23] A RANDOMIZED TRIAL OF MAINTENANCE THERAPY WITH INTRON-A FOLLOWING HIGH-DOSE MELPHALAN AND ABMT IN MYELOMA
    POWLES, R
    CUNNINGHAM, D
    MALPAS, JS
    RAJE, N
    MILAN, S
    SINGHAL, S
    MEHTA, J
    VINER, C
    TRELEAVAN, J
    RAYMOND, J
    BLOOD, 1994, 84 (10) : A535 - A535
  • [24] Primary refractory multiple myeloma - what role for high dose melphalan?
    Giralt, Sergio
    LEUKEMIA & LYMPHOMA, 2020, 61 (12) : 2785 - 2785
  • [25] ORAL COMPLICATIONS OF HIGH-DOSE MELPHALAN IN MULTIPLE-MYELOMA
    BARRETT, AP
    BUCKLEY, DJ
    ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS, 1987, 64 (02): : 264 - 267
  • [26] MULTIPLE-MYELOMA TREATED WITH HIGH-DOSE INTRAVENOUS MELPHALAN
    SELBY, PJ
    MCELWAIN, TJ
    NANDI, AC
    PERREN, TJ
    POWLES, RL
    TILLYER, CR
    OSBORNE, RJ
    SLEVIN, ML
    MALPAS, JS
    BRITISH JOURNAL OF HAEMATOLOGY, 1987, 66 (01) : 55 - 62
  • [27] Prospective oral mucositis audit (POMA): Occurrence and consequences of severe oral mucositis in high dose melphalan and beam conditioning
    Blijlevens, N.
    McCann, S.
    Bacon, P.
    Quinn, B.
    Schwenkglcnks, M.
    Stone, R.
    Pico, J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (02) : 73 - 73
  • [28] RETRACTED: Gastrointestinal Bleeding Secondary to High-Dose Melphalan Pretreatment in Patients with Multiple Myeloma Was Associated with the Mode of Melphalan Administration (Retracted Article)
    Ge, Qunfang
    Wang, Yi
    Zhu, Huiling
    Xu, Kaihong
    Sheng, Lixia
    Yan, Xiaoyan
    Ouyang, Guifang
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2022, 2022
  • [29] Oral mucositis (OM) and outcomes of autologous (AU) hematopoietic stem cell transplantation (HSCT) following high-dose melphalan (MP) conditioning for multiple myeloma (MM).
    Oster, G
    Vera-Llonch, M
    Ford, C
    Lu, J
    Khazanov, I
    Sonis, S
    BLOOD, 2005, 106 (11) : 390A - 390A
  • [30] Duration of ulcerative mucositis and outcomes of autologous (AU) hematopoietic stem cell transplantation (HSCT) following high-dose melphalan (MP) conditioning for multiple myeloma (MM)
    Oster, G
    Vera-Llonch, M
    Ford, C
    Lu, J
    Khazaliov, I
    Sonis, S
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) : 97 - 97
12345